TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to return to baseline SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of desaturation (change in SpO2 > 3%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma MGO concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in patients' BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in carers' distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neurobehavioral status of the baby
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute pain at activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smallest percentage difference needed to detect a genuine change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: catheter survival at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: probability of episodes of peritonitis
Endpoint domain: Adverse events/effects
Primary endpoint: probability of exit-site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of low sexual desire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in heavy alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: J-Tpeakc prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tpeak-Tend prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Failure rate of mandibular lingual retainers
Endpoint domain: Mortality/survival
Primary endpoint: Half-life of PAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of PAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of PAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: event rates
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in FI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: injury to lung tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in lower limb edema volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median dietary intake of energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median dietary intake of proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median dietary intake of carbohydrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median dietary intake of fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Twenty-eight day mortality
Endpoint domain: Mortality/survival
Primary endpoint: Normalization of pHi within 24 hours of resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of reinterventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 180-day cardiovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: Nasal projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: caloric intake reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perinatal loss
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of death
Endpoint domain: Adverse events/effects
Primary endpoint: Transvalvular flow velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cone size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between observed and child-reported break-time foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average amount of SSB consumed by children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg extension peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg flexion peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG amplitude for the superficial quadriceps femoris muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RPS-near scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly phosphate removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: American Urological Association symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak urinary flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-void residual urine volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment effectiveness for lower respiratory tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HH compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wound-fluid levels of HIF-1α
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wound-fluid levels of VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean hemoglobin drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: anesthetic cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urinary H2O2 excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of crowns after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free of gingival inflammation after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction with catheterization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain scores after application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favourable outcome at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence in ability to adhere to treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intentions to adhere to periodontal management
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Perceived effectiveness of periodontal disease treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of vomiting episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of clinical agreement between VAS techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proANP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: heart failure symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual Flow Duration (MFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Efficacy Rate (ER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deaths related to abdominal aortic aneurysm
Endpoint domain: Mortality/survival
Primary endpoint: Average number of pain days after intravitreal injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of chromium on type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean hypoglycaemic episodes per patient
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial blood glucose levels after main meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mood symptoms improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in PDGF‐AA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensitivity of immunocapture technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of immunocapture technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sputum/blood eosinophilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoluminal repair failure rate
Endpoint domain: Mortality/survival
Primary endpoint: Local vascular complications
Endpoint domain: Adverse events/effects
Primary endpoint: Aneurysm enlargement beyond 5 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: return rate of male donors
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in whole-body insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in plasma apoC-III levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in triglyceride (TG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in CT number per gram of iodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphine blood concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial hyperlipidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental glucose peak (IGP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental area under the curve for glucose (IAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vaccine efficacy against VCD
Endpoint domain: Mortality/survival
Primary endpoint: Vaccine efficacy against severe VCD
Endpoint domain: Mortality/survival
Primary endpoint: Vaccine efficacy against hospitalization for dengue
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of CTA for large-vessel vasospasm detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Negative Predictive Value (NPV) of CTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: amnesia on a cued recall task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: free recall for post-drug events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Constant Power Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month alcohol outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone pain symptoms alleviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum vaginal squeeze pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of ICIQ-SF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phase shifts in DLMoff
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival at 36 months
Endpoint domain: Mortality/survival
Primary endpoint: EDSS regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSFC performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDMT performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV vaccine awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention to receive HPV vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ASR(GSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte glutathione concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS levels at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with ACE inhibitor intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean duration of menstrual flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major and minor complications
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative glycemia values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of samples with dapivirine >95 pg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean glucose nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of analgesic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Chinese medical syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric means ratios of ticlopidine AUC(0-last), AUC(0-infinity), and C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of progression to AD
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive function Neuro-QoL
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: leg extensor peak power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma IL-18 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight loss after 1 year of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV infection risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: median increase in triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lag phase of Cu‐catalyzed LDL oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidation rate of LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative rate of clinical and hemodynamic success after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary patency at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICER per QALY gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total gadolinium-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of benzodiazepine therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: improvements in harsh/critical parenting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvements in nurturing/supportive parenting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvements in discipline competence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Denervation success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the Steiner score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median failure load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesions free of Leishmania
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cosmetic outcome after PDT
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean pulmonary to systemic arterial pressure ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative bioavailability of prolonged-release tacrolimus suspension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cmax (peak blood concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median Tmax (time to peak concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Foot pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of keratotic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Euthyroid status maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hypothyroidism rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hepatic arterial resistive index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Renal arterial resistive index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Occurrence of OCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: body density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fat weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccination health beliefs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pupil absence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of patients requiring rescue pethidine analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: 24-h thyroid (131)I uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: number of cured patients
Endpoint domain: Mortality/survival
Primary endpoint: Total scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in IHTG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Waist-to-hip ratio change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of follow-up visits per year
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cost analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sensitivity of quantization diagnostic standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of quantization diagnostic standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy rating of quantization diagnostic standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccination uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: actuarial survival after complete metastasectomy
Endpoint domain: Mortality/survival
Primary endpoint: quality of post-operative reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional score using the modified Merle D'Aubinge and Postel score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Onset of Postpartum Depression (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal perspectives of the program
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Respiratory rate improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes